Adma Biologics Inc. is a biotechnology company that focuses on the development, manufacture, and commercialization of specialty plasma-derived biologics for the treatment and prevention of infectious ... Adma Biologics Inc. is a biotechnology company that focuses on the development, manufacture, and commercialization of specialty plasma-derived biologics for the treatment and prevention of infectious diseases. At the core of its operations is the processing of human plasma to produce immunoglobulin products aimed at addressing immune deficiencies and other complex health conditions. The company's prominent products include Bivigam, an intravenous immunoglobulin used for the treatment of primary humoral immunodeficiency, and Asceniv, another intravenous immunoglobulin specifically tailored with hyperimmune antibodies.
Adma Biologics serves critical roles within the healthcare sector, particularly in treating patients with immune system disorders, thus supporting a niche yet vital component of the pharmaceutical supply chain. Their products are crucial in meeting the demands of patients who require regular immune system support, distilling unique proteins and antibodies from donated plasma to help bolster patient health. With headquarters in Ramsey, New Jersey, and Boca Raton, Florida, the company plays a significant role in the advancements of plasma-derived therapeutics, catering to both domestic and international needs.
Pending data availability
Waste Management Data missing for ADMA Biologics
We haven’t collected Waste Management data for ADMA Biologics yet, or the company
hasn’t made it publicly available.